The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days. Valu ...

In the last reported quarter, the company delivered an earnings surprise of 4.11%. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 6.12%. The Zacks Consensus Estimate for revenues is pegged at $73.58 billion, indicating an improvement of 9.9% from the top line reported in the prior-year quarter. The consensus mark for earnings is pinned at $3.18 per share, implying growth of 8.9% from the year-ago quarter's recorded number. Sustained strong growth in spec ...

This prescription drug distributor has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 9.40%. For Cencora, estimates have been trending higher, thanks in part to this earnings surprise history. And when you The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related ...

Core Insights - LYTENAVA™ (bevacizumab gamma) has received marketing authorization from the UK MHRA for the treatment of wet AMD, following similar approval from the European Commission [2][3][11] - The commercial launch of LYTENAVA™ in the EU and UK is anticipated in the first calendar quarter of 2025 [2][4][11] - Outlook Therapeutics has formed a strategic partnership with Cencora to support the commercial launches, providing comprehensive services including pharmacovigilance and market access support [5][6][11] Company Overview - Outlook Therapeutics is focused on the development and commercialization of ONS-5010/LYTENAVA™ for retinal diseases, specifically wet AMD [11] - LYTENAVA™ is the first authorized ophthalmic formulation of bevacizumab for treating wet AMD in the EU and UK [2][11] - In the United States, LYTENAVA™ is still under investigation and is being evaluated in a non-inferiority study for wet AMD [9][11] Regulatory Milestones - The marketing authorization application to the MHRA was completed under the new International Recognition Procedure, allowing reliance on the European Medicines Agency's positive opinion [3] - The approval from the MHRA is seen as a significant milestone for Outlook Therapeutics, paving the way for the expected commercial launch [5][4] Strategic Partnerships - Cencora will assist in the launch of LYTENAVA™ by providing services such as regulatory affairs, quality management, and distribution [6][12] - The collaboration aims to ensure timely and reliable access to LYTENAVA™ for healthcare providers and patients [6][12]

Company Performance - Cencora's shares have risen 11% year to date, outperforming the industry growth of 4.1% and the S&P 500 Index increase of 15.2% in the same period [1] - Cencora's shares lost 3.9% on June 27, followed by a further 1.3% decline in after-hours trading, attributed to the invalidation of a previously-settled opioid litigation by the Supreme Court and concerns over the retail pharmacy market [11] Legal and Regulatory Environment - The recent Supreme Court ruling invalidated a $6 billion settlement related to Purdue Pharma, which would have protected the Sackler family from future financial claims, potentially allowing families affected by the opioid crisis to pursue legal claims [2][8] - Four states opted out of the national settlement in 2021, continuing their legal battles against opioid-related entities [3] - The invalidation of the settlement raises concerns for further court rulings in favor of opioid-abuse victims, impacting companies like Cencora, McKesson, and Cardinal Health [12] Market Dynamics - Walgreens Boots, Cencora's largest customer, experienced a more than 22% decline in share price on June 27, which is expected to reflect in Cencora's third-quarter fiscal 2024 results [4] - The stock decline for Cencora is likely linked to rising concerns regarding opioid-abuse litigation and assumed weakness in the retail pharmacy market following lower-than-expected results from Walgreens Boots [9] Financial Implications - Cencora, along with McKesson, Johnson & Johnson, and Cardinal Health, has set aside reserves to meet the multi-year $26 billion settlement related to the opioid crisis, and any invalidation of this settlement may increase their financial burden and legal expenses [13] - The shares of other related companies, such as McKesson and Cardinal Health, also declined by 1.1% and 1.5%, respectively, on June 27 due to the same legal and market pressures [14] Future Outlook - Cencora has the potential for a turnaround due to its multinational distribution footprint and global commercialization services, which position it as a natural partner for manufacturers [6] - Improving patient access to medical care, enhanced economic conditions, and favorable population demographics are expected to benefit the pharmaceutical segment in upcoming quarters [6]

1 IF D H HT T 100 - 100 1 i T 1 Pgiam/iStock via Getty Images Investment Update Since my last publication on Cencora (NYSE:COR) shares have continued to advance and now trade 13% higher. This marks a substantial gain from the original buy thesis I presented on COR in 2023. Analysts in a Bernstein-Societe Generale rated COR a high-quality stock with high ROIC trading at sensible valuations in a recent analysis. This is exactly the sentiment I have held with COR since day on, and this has not changed. Earning ...

The rally in the company's share price can be attributed to the robust growth in the company's U.S. Healthcare Solutions segment. The optimism led by a solid second-quarter fiscal 2024 performance and robust business potential are expected to contribute further. Cencora exited second-quarter fiscal 2024 with decent results. The company witnessed solid top-line and bottom-line performances in the reported quarter, which is likely to have aided in the price growth. In the fiscal second quarter, Cencora's U.S. ...

Cencora, Inc. (COR) is well-poised for growth on the back of robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern. COR currently reports under two segments — U.S. Healthcare Solutions and International Healthcare Solutions. The first segment comprises the legacy Pharmaceutical Distribution Services (excluding Proforma), MWI Animal Health, Xcenda, Lash Group and ICS 3PL. It benefits from an increasing volume and expanding customer base. Strong organic grow ...

Walgreens has sold more shares of drug distributor Cencora for proceeds of about $400 million, which ... [+] will be used for "debt paydown and general corporate purposes."In this 2013 photo, a sign marks the entrance to a Walgreens store in San Francisco's upscale Union Square shopping district. (Photo by Robert Alexander/Getty Images) Getty Images The stock sale, which comes as chief executive officer Tim Wentworth works on a financial turnaround of the iconic drugstore chain, brings Walgreens stake in Ce ...

For the quarter ended March 2024, Cencora (COR) reported revenue of $68.41 billion, up 7.8% over the same period last year. EPS came in at $3.80, compared to $3.50 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $70.35 billion, representing a surprise of -2.75%. The company delivered an EPS surprise of +4.11%, with the consensus EPS estimate being $3.65.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expect ...